Filippo Crivelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Filippo Crivelli has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Annamaria Piva
Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy
40 shared publications - Barbara Frossi
Immunology Section, Department of Medicine, University of Udine, 33100 Udine, Italy
40 shared publications - Carlo Pucillo
Department of Medicine, University of Udine
40 shared publications - Claudia Chiodoni
Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
40 shared publications - Claudia Enriquez
Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. 1
40 shared publications - Claudio Tripodo
Tumor Immunology Unit, University of Palermo, Palermo, Italy
40 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S6. Quantification of western blot. A. Quantification of western blot reported in Fig. 3G. Western blots were validated twice. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used for the analysis of significance between samples. P-values are reported as: *, P < 0.05; **, P <0.01; ***, P <0.001; ****, P <0.0001. Where P-value is not indicated, the comparison between groups is not statistically significant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S6. Quantification of western blot. A. Quantification of western blot reported in Fig. 3G. Western blots were validated twice. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used for the analysis of significance between samples. P-values are reported as: *, P < 0.05; **, P <0.01; ***, P <0.001; ****, P <0.0001. Where P-value is not indicated, the comparison between groups is not statistically significant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S1. Flow cytometry evaluation of murine MC purity and maturation in vitro. A. Gating strategy used to evaluate the purity and maturation of WT, OPN-/-, MyD88-/- and TNFa-/-MCs by flow cytometry. Mature MC population is identified as c-Kit+FceRI+.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S1. Flow cytometry evaluation of murine MC purity and maturation in vitro. A. Gating strategy used to evaluate the purity and maturation of WT, OPN-/-, MyD88-/- and TNFa-/-MCs by flow cytometry. Mature MC population is identified as c-Kit+FceRI+.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S2. OPN evaluation in bone marrow-derived MCs. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of WT and OPN-/- MCs showed in Fig. 1A B. Representative images of 3 different biological replicates of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue), in WT and OPN-/- MCs. These pictures were used for the quantification reported in Fig. 1B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S2. OPN evaluation in bone marrow-derived MCs. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of WT and OPN-/- MCs showed in Fig. 1A B. Representative images of 3 different biological replicates of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue), in WT and OPN-/- MCs. These pictures were used for the quantification reported in Fig. 1B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 3 - List of putative NEPC-specific surface TLR ligands
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 3 - List of putative NEPC-specific surface TLR ligands
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 4 - transcript levels of the 29 TLR ligands measured by high throughput customized Taqman assay
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 4 - transcript levels of the 29 TLR ligands measured by high throughput customized Taqman assay
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 1 - list of antibodies used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 1 - list of antibodies used in the study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S7. Flow cytometry characterization of TNFa receptors and TNFa production. A. List of cytokines and chemokines tested through a multiplex immunoassay (Procarta-plex by Thermofisher) in the supernatants of ST4787 or T23 cells cultured either alone or in the presence of WT, OPN-/-, or MyD88-/- MCs. B.-C. Flow cytometry evaluation of TNFRs (CD120a and CD120b) on adenocarcinoma (T23 murine, 22Rv1 human) and NEPC (TC566 and TC411K murine, and LASCPC-01 human) cells. D. Gating strategy applied for intracellular detection of TNFa in MCs (CD49f-CD45+) by flow cytometry, in the co-cultures between MCs and tumor cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S7. Flow cytometry characterization of TNFa receptors and TNFa production. A. List of cytokines and chemokines tested through a multiplex immunoassay (Procarta-plex by Thermofisher) in the supernatants of ST4787 or T23 cells cultured either alone or in the presence of WT, OPN-/-, or MyD88-/- MCs. B.-C. Flow cytometry evaluation of TNFRs (CD120a and CD120b) on adenocarcinoma (T23 murine, 22Rv1 human) and NEPC (TC566 and TC411K murine, and LASCPC-01 human) cells. D. Gating strategy applied for intracellular detection of TNFa in MCs (CD49f-CD45+) by flow cytometry, in the co-cultures between MCs and tumor cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S5. Expression of OPN in MC/9 cells and effect on T23 cell proliferation. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of MC/9, MC/9-CTR, MC/9-OPNf, and MC/9-iOPN cells showed in Fig. 2E. B. Quantification of A as percentage of OPN positive cells. C. Murine adenocarcinoma (T23) cells (50.000/well) were cultured either alone or with MC/9, MC/9-CTR, MC/9-OPNf or MC/9-iOPN cells (tumor cell:MC ratio 1:1). After 4 days the growth rate of cancer cells was evaluated through trypan blue count. Cancer cells and MC/9 could be distinguished thanks to their grown in adhesion or suspension, respectively. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used: *, P < 0.05; **, P <0.01. Where P-value is not indicated, the comparison between groups is not statistically significant.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S5. Expression of OPN in MC/9 cells and effect on T23 cell proliferation. A. Separate channels of immunofluorescence for DAPI (cyan), OPN (red) and WGA (blue) of MC/9, MC/9-CTR, MC/9-OPNf, and MC/9-iOPN cells showed in Fig. 2E. B. Quantification of A as percentage of OPN positive cells. C. Murine adenocarcinoma (T23) cells (50.000/well) were cultured either alone or with MC/9, MC/9-CTR, MC/9-OPNf or MC/9-iOPN cells (tumor cell:MC ratio 1:1). After 4 days the growth rate of cancer cells was evaluated through trypan blue count. Cancer cells and MC/9 could be distinguished thanks to their grown in adhesion or suspension, respectively. All histograms depict mean ± SD of biological replicates (represented by dots). One-way ANOVA followed by Tukey’s multiple comparison test was used: *, P < 0.05; **, P <0.01. Where P-value is not indicated, the comparison between groups is not statistically significant.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S4. Characterization of additional cell lines. A. Immunofluorescence for DAPI (blue) and CGA (red) on murine NEPC cells (TC566 and TC411K). B. Immunofluorescence for DAPI (blue) and OPN (red) on HMC-1 cells. C. Western blot for OPN in HMC-1 cells treated or not with Brefeldin A (BFA; 5 g/ml). Vinculin was evaluated as housekeeping control. D. Gating strategy applied to distinguish human NEPC cells (CD49f+c-Kit-) from HMC-1 MCs (CD49f-c-Kit+) by flow cytometry. E. OPN evaluation by ELISA (left panel) or real time PCR (the Spp1 transcript; right panel) in WT and OPN−/− MCs, and in MC/9, T23, and ST4787 cells. F. Elisa for OPN in parental MC/9 cells and in MC/9-CTR, MC/9-OPNf, MC/9-iOPN cells. T23 cells were used as control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary Figure S4. Characterization of additional cell lines. A. Immunofluorescence for DAPI (blue) and CGA (red) on murine NEPC cells (TC566 and TC411K). B. Immunofluorescence for DAPI (blue) and OPN (red) on HMC-1 cells. C. Western blot for OPN in HMC-1 cells treated or not with Brefeldin A (BFA; 5 g/ml). Vinculin was evaluated as housekeeping control. D. Gating strategy applied to distinguish human NEPC cells (CD49f+c-Kit-) from HMC-1 MCs (CD49f-c-Kit+) by flow cytometry. E. OPN evaluation by ELISA (left panel) or real time PCR (the Spp1 transcript; right panel) in WT and OPN−/− MCs, and in MC/9, T23, and ST4787 cells. F. Elisa for OPN in parental MC/9 cells and in MC/9-CTR, MC/9-OPNf, MC/9-iOPN cells. T23 cells were used as control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 2 - list of siRNA and Taqman assays used in the study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer
Supplementary table 2 - list of siRNA and Taqman assays used in the study